Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases - Seite 2

Søren Lemonius, General Partner at Sunstone Life Science Ventures, commented: "We are delighted to further support Teitur at this pivotal time of Company growth and development. Our passion is to enable and empower therapeutic innovation that has the ability to improve patient outcomes and we believe Teitur's cyclic peptides is yet another excellent example of the breakthrough science coming out of the Scandinavian biotech ecosystem."

Casper Breum, Managing Partner at Sound Bioventures added: "We are proud to support such an innovative Company that has the potential to make a meaningful impact against neurodegenerative diseases and improve the quality of life of patients, and we look forward to supporting the Company through its next stage of growth."

In conjunction with the Series A financing, Charles Large will continue as Chairman of the Board at Teitur, while Søren Lemonius, Casper Breum, Fredrik Lehmann, Milla Koistinaho and Susanne Stuffers will join the Teitur Board of Directors.

About Teitur Trophics

Teitur Trophics, founded by Simon Molgaard, Anders Dalby, Mathias Ollendorff and Simon Glerup, is a biotech company that targets neurodegenerative diseases, based in Aarhus, Denmark. It is developing first-in-class circular peptides for treating neurodegenerative disorders where there are no treatments currently available, including Parkinson's Disease, Frontotemporal Dementia and Huntington's Disease. Its lead drug candidate, TT-P34 works by clearing the toxic protein deposits implicated in neurodegenerative diseases, restoring the function of mitochondria in affected brain cells and promoting pro-survival signaling. For more information, please visit: www.TeiturTrophics.com

About Sunstone Life Science Ventures

Sunstone Life Science Ventures is an independent European venture capital investment firm founded in 2007 by an international team of industry experts with combined entrepreneurial, operational and financial experience. Managing total funds of €500 million, Sunstone Life Science Ventures focuses on developing and expanding early–stage Life Science companies with strong potential to achieve global success in their markets. Since the inception, Sunstone Life Science Ventures has invested in more than 50 companies in the areas of pharmaceuticals, medical technologies and diagnostics, and has completed more than 20 successful IPOs and large M&A transactions. For more information, please visit: https://sunstone.eu/